DrugCendR Announces Initiation of CEND1-001 Phase 1 Trial for Metastatic Pancreatic Cancer

Main image Main image

Cend Therapeutics In The News

DrugCendR Announces Initiation of CEND1-001 Phase 1 Trial for Metastatic Pancreatic Cancer
August 13, 2018

DrugCendR Inc., a biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery in solid tumors, announced today the treatment of the first patient in a Phase 1 clinical trial evaluating its lead compound CEND-1 (scientifically known as iRGD), in patients with metastatic pancreatic adenocarcinoma (CEND1-001, Clinical trial reference NCT03517176).


“Treating the first patient is an exciting milestone for our technology platform and for the company.” said Erkki Ruoslahti, President and CEO of DrugCendR Inc. “We chose to conduct the first study in pancreatic cancer, a cancer that is in desperate need of more effective therapies and shown to respond to CEND-1. Studies in preclinical models conducted all over the world also show that CEND-1 has wider potential; it enhances the therapy of many types of cancers by many types of drugs. We hope to make that potential a reality in the treatment of human cancer.”


Chief Operating Officer, Harri Jarvelainen continues, “We initiated our IND-enabling program a year ago so it is a great achievement to start dosing in this multi-site trial already now. Data from more than 100 publications have consistently demonstrated that CEND-1 is effective in the treatment of various types of solid tumors – but importantly, it is also a safe and well-tolerated compound, thanks to its tumor specific mechanism of action. As the extent of preclinical validation is almost unprecedented, we have a high confidence in the clinical translation of our therapy and hope that it will be soon available to patients with this and other cancers with high unmet medical need.”


Click here to read the full news release.

For more information.



INNOVATION Kyoto 2016 LPs Completes Strategic Investment in DrugCendR Inc.

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.

“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”

Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.